AG˹ٷ

STOCK TITAN

[Form 4] Carvana Co. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

agilon health, inc. (AGL) � Form 4, filed 08/05/2025

Chief Legal Officer Denise Zamore reported a Rule 16b-3 “F� transaction dated 08/01/2025. The issuer withheld 915 common shares at an indicated $1.70 per share to cover income-tax obligations arising from the net settlement of previously granted restricted stock units. Because the shares were withheld by the company rather than sold in the open market, Zamore’s underlying economic exposure to AGL stock is largely unchanged. Following the withholding, she directly owns 443,125 shares (including unvested RSUs); no derivative securities were acquired or disposed of. No other officers or directors were involved, and no additional transactions were disclosed.

The filing is routine and does not signal an intentional sale or purchase. Investors may view the update as neutral but can use it to monitor insider ownership trends and share-based compensation practices.

agilon health, inc. (AGL) � Modulo 4, presentato il 05/08/2025

La Chief Legal Officer Denise Zamore ha comunicato una transazione ai sensi della Regola 16b-3 “F� datata 01/08/2025. L’emittente ha trattenuto 915 azioni ordinarie al prezzo indicato di 1,70$ per azione per coprire le obbligazioni fiscali derivanti dal regolamento netto di unità azionarie ristrette precedentemente assegnate. Poiché le azioni sono state trattenute dalla società anziché vendute sul mercato aperto, l’esposizione economica sottostante di Zamore alle azioni AGL rimane sostanzialmente invariata. Dopo la trattenuta, possiede direttamente 443.125 azioni (incluse le RSU non maturate); non sono stati acquisiti o ceduti titoli derivati. Nessun altro dirigente o membro del consiglio è stato coinvolto e non sono state divulgate ulteriori transazioni.

La comunicazione è di routine e non indica una vendita o un acquisto intenzionale. Gli investitori possono considerare l’aggiornamento neutro, ma può essere utile per monitorare le tendenze di proprietà degli insider e le pratiche di compensazione basate sulle azioni.

agilon health, inc. (AGL) � Formulario 4, presentado el 05/08/2025

La Directora Legal Denise Zamore reportó una transacción bajo la Regla 16b-3 “F� con fecha 01/08/2025. El emisor retuvo 915 acciones ordinarias a un precio indicado de 1,70$ por acción para cubrir obligaciones fiscales derivadas de la liquidación neta de unidades restringidas de acciones previamente otorgadas. Debido a que las acciones fueron retenidas por la compañía en lugar de venderse en el mercado abierto, la exposición económica subyacente de Zamore a las acciones de AGL permanece en gran medida sin cambios. Tras la retención, posee directamente 443,125 acciones (incluyendo RSU no adquiridas); no se adquirieron ni dispusieron valores derivados. Ningún otro funcionario o director estuvo involucrado y no se divulgaron transacciones adicionales.

La presentación es rutinaria y no indica una venta o compra intencional. Los inversores pueden considerar esta actualización como neutral, pero puede usarse para monitorear las tendencias de propiedad interna y las prácticas de compensación basadas en acciones.

agilon health, inc. (AGL) � 2025� 8� 5� 제출� Form 4

최고법률책임� Denise Zamore가 2025� 8� 1일자 Rule 16b-3 “F� 거래� 보고했습니다. 발행사는 이전� 부여된 제한 주식 단위� 순정산에� 발생� 소득� 의무� 충당하기 위해 주당 1.70달러� 표시� 915 보통�� 원천징수했습니다. 회사가 주식� 시장에서 매도하지 않고 원천징수했기 때문� Zamore� AGL 주식� 대� 실질적인 경제� 노출은 거의 변하지 않았습니�. 원천징수 � 그녀� 직접 443,125�� 보유하고 있으�(미확� RSU 포함), 파생 증권� 취득이나 처분은 없었습니�. 다른 임원이나 이사� 관련되지 않았으며 추가 거래� 공개되지 않았습니�.

이번 제출은 일상적인 것으� 의도적인 매매� 의미하지 않습니다. 투자자들은 � 업데이트� 중립적으� � � 있으�, 내부� 소유 동향 � 주식 기반 보상 관행을 모니터링하는 � 활용� � 있습니다.

agilon health, inc. (AGL) � Formulaire 4, déposé le 05/08/2025

La directrice juridique Denise Zamore a rapporté une transaction selon la règle 16b-3 « F » datée du 01/08/2025. L’émetteur a retenu 915 actions ordinaires au prix indiqué de 1,70 $ par action pour couvrir les obligations fiscales découlant du règlement net d’unités d’actions restreintes précédemment attribuées. Comme les actions ont été retenues par la société plutôt que vendues sur le marché ouvert, l’exposition économique sous-jacente de Zamore aux actions AGL reste en grande partie inchangée. Après la retenue, elle possède directement 443 125 actions (y compris les RSU non acquises) ; aucun titre dérivé n’a été acquis ou cédé. Aucun autre dirigeant ou administrateur n’a été impliqué, et aucune autre transaction n’a été divulguée.

Le dépôt est de routine et ne signale aucune vente ou achat intentionnel. Les investisseurs peuvent considérer cette mise à jour comme neutre, mais elle peut être utilisée pour suivre les tendances de propriété des initiés et les pratiques de rémunération basées sur les actions.

agilon health, inc. (AGL) � Formular 4, eingereicht am 05.08.2025

Die Chief Legal Officer Denise Zamore meldete eine Transaktion gemäß Regel 16b-3 „F� vom 01.08.2025. Der Emittent behielt 915 Stammaktien zu einem angegebenen Preis von 1,70 USD pro Aktie ein, um Steuerverpflichtungen aus der Nettosettlement von zuvor gewährten Restricted Stock Units abzudecken. Da die Aktien vom Unternehmen einbehalten und nicht auf dem offenen Markt verkauft wurden, bleibt Zamores zugrunde liegendes wirtschaftliches Engagement an AGL-Aktien weitgehend unverändert. Nach dem Einbehalt besitzt sie direkt 443.125 Aktien (einschließlich nicht unverfallener RSUs); es wurden keine Derivate erworben oder veräußert. Keine weiteren Führungskräfte oder Direktoren waren beteiligt, und es wurden keine zusätzlichen Transaktionen offengelegt.

Die Meldung ist routinemäßig und signalisiert keinen beabsichtigten Kauf oder Verkauf. Investoren können das Update neutral bewerten, es aber zur Beobachtung von Insider-Besitztrends und aktienbasierten Vergütungspraktiken nutzen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding transaction; negligible impact on ownership or valuation.

The "F" code indicates shares withheld by the company to satisfy taxes on vested RSUs. Only 915 shares (<1% of Zamore’s 443k position) were involved, so the move does not meaningfully alter insider alignment or market float. No price discovery or sentiment signal accompanies the action. I consider the disclosure immaterial for valuation or trading decisions.

TL;DR: Standard compliance filing; governance posture unchanged.

The filing demonstrates timely Section 16 compliance and transparent reporting of equity-based compensation settlements. Because it involves mandatory tax withholding rather than elective selling, it poses no governance red flag. Insider ownership remains substantial, supporting ongoing alignment with shareholders.

agilon health, inc. (AGL) � Modulo 4, presentato il 05/08/2025

La Chief Legal Officer Denise Zamore ha comunicato una transazione ai sensi della Regola 16b-3 “F� datata 01/08/2025. L’emittente ha trattenuto 915 azioni ordinarie al prezzo indicato di 1,70$ per azione per coprire le obbligazioni fiscali derivanti dal regolamento netto di unità azionarie ristrette precedentemente assegnate. Poiché le azioni sono state trattenute dalla società anziché vendute sul mercato aperto, l’esposizione economica sottostante di Zamore alle azioni AGL rimane sostanzialmente invariata. Dopo la trattenuta, possiede direttamente 443.125 azioni (incluse le RSU non maturate); non sono stati acquisiti o ceduti titoli derivati. Nessun altro dirigente o membro del consiglio è stato coinvolto e non sono state divulgate ulteriori transazioni.

La comunicazione è di routine e non indica una vendita o un acquisto intenzionale. Gli investitori possono considerare l’aggiornamento neutro, ma può essere utile per monitorare le tendenze di proprietà degli insider e le pratiche di compensazione basate sulle azioni.

agilon health, inc. (AGL) � Formulario 4, presentado el 05/08/2025

La Directora Legal Denise Zamore reportó una transacción bajo la Regla 16b-3 “F� con fecha 01/08/2025. El emisor retuvo 915 acciones ordinarias a un precio indicado de 1,70$ por acción para cubrir obligaciones fiscales derivadas de la liquidación neta de unidades restringidas de acciones previamente otorgadas. Debido a que las acciones fueron retenidas por la compañía en lugar de venderse en el mercado abierto, la exposición económica subyacente de Zamore a las acciones de AGL permanece en gran medida sin cambios. Tras la retención, posee directamente 443,125 acciones (incluyendo RSU no adquiridas); no se adquirieron ni dispusieron valores derivados. Ningún otro funcionario o director estuvo involucrado y no se divulgaron transacciones adicionales.

La presentación es rutinaria y no indica una venta o compra intencional. Los inversores pueden considerar esta actualización como neutral, pero puede usarse para monitorear las tendencias de propiedad interna y las prácticas de compensación basadas en acciones.

agilon health, inc. (AGL) � 2025� 8� 5� 제출� Form 4

최고법률책임� Denise Zamore가 2025� 8� 1일자 Rule 16b-3 “F� 거래� 보고했습니다. 발행사는 이전� 부여된 제한 주식 단위� 순정산에� 발생� 소득� 의무� 충당하기 위해 주당 1.70달러� 표시� 915 보통�� 원천징수했습니다. 회사가 주식� 시장에서 매도하지 않고 원천징수했기 때문� Zamore� AGL 주식� 대� 실질적인 경제� 노출은 거의 변하지 않았습니�. 원천징수 � 그녀� 직접 443,125�� 보유하고 있으�(미확� RSU 포함), 파생 증권� 취득이나 처분은 없었습니�. 다른 임원이나 이사� 관련되지 않았으며 추가 거래� 공개되지 않았습니�.

이번 제출은 일상적인 것으� 의도적인 매매� 의미하지 않습니다. 투자자들은 � 업데이트� 중립적으� � � 있으�, 내부� 소유 동향 � 주식 기반 보상 관행을 모니터링하는 � 활용� � 있습니다.

agilon health, inc. (AGL) � Formulaire 4, déposé le 05/08/2025

La directrice juridique Denise Zamore a rapporté une transaction selon la règle 16b-3 « F » datée du 01/08/2025. L’émetteur a retenu 915 actions ordinaires au prix indiqué de 1,70 $ par action pour couvrir les obligations fiscales découlant du règlement net d’unités d’actions restreintes précédemment attribuées. Comme les actions ont été retenues par la société plutôt que vendues sur le marché ouvert, l’exposition économique sous-jacente de Zamore aux actions AGL reste en grande partie inchangée. Après la retenue, elle possède directement 443 125 actions (y compris les RSU non acquises) ; aucun titre dérivé n’a été acquis ou cédé. Aucun autre dirigeant ou administrateur n’a été impliqué, et aucune autre transaction n’a été divulguée.

Le dépôt est de routine et ne signale aucune vente ou achat intentionnel. Les investisseurs peuvent considérer cette mise à jour comme neutre, mais elle peut être utilisée pour suivre les tendances de propriété des initiés et les pratiques de rémunération basées sur les actions.

agilon health, inc. (AGL) � Formular 4, eingereicht am 05.08.2025

Die Chief Legal Officer Denise Zamore meldete eine Transaktion gemäß Regel 16b-3 „F� vom 01.08.2025. Der Emittent behielt 915 Stammaktien zu einem angegebenen Preis von 1,70 USD pro Aktie ein, um Steuerverpflichtungen aus der Nettosettlement von zuvor gewährten Restricted Stock Units abzudecken. Da die Aktien vom Unternehmen einbehalten und nicht auf dem offenen Markt verkauft wurden, bleibt Zamores zugrunde liegendes wirtschaftliches Engagement an AGL-Aktien weitgehend unverändert. Nach dem Einbehalt besitzt sie direkt 443.125 Aktien (einschließlich nicht unverfallener RSUs); es wurden keine Derivate erworben oder veräußert. Keine weiteren Führungskräfte oder Direktoren waren beteiligt, und es wurden keine zusätzlichen Transaktionen offengelegt.

Die Meldung ist routinemäßig und signalisiert keinen beabsichtigten Kauf oder Verkauf. Investoren können das Update neutral bewerten, es aber zur Beobachtung von Insider-Besitztrends und aktienbasierten Vergütungspraktiken nutzen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GARCIA ERNEST C. III

(Last) (First) (Middle)
C/O CARVANA CO.
300 E. RIO SALADO PARKWAY

(Street)
TEMPE AZ 85281

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CARVANA CO. [ CVNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 08/01/2025 S 406(1) D $365.28(2) 591,034 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 406(1) D $365.28(2) 691,034 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 494(1) D $366.84(5) 590,540 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 494(1) D $366.84(5) 690,540 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 700(1) D $367.96(6) 589,840 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 700(1) D $367.96(6) 689,840 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 300(1) D $368.62(7) 589,540 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 300(1) D $368.62(7) 689,540 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 800(1) D $369.81(8) 588,740 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 800(1) D $369.81(8) 688,740 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 500(1) D $370.97(9) 588,240 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 500(1) D $370.97(9) 688,240 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 300(1) D $372.16(10) 587,940 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 300(1) D $372.16(10) 687,940 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 550(1) D $373.11(11) 587,390 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 550(1) D $373.11(11) 687,390 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 300(1) D $374.55(12) 587,090 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 300(1) D $374.55(12) 687,090 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 300(1) D $375.79(13) 586,790 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 300(1) D $375.79(13) 686,790 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 150(1) D $377.03(14) 586,640 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 150(1) D $377.03(14) 686,640 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 100(1) D $377.94(15) 586,540 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 100(1) D $377.94(15) 686,540 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 50(1) D $378.66 586,490 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 50(1) D $378.66 686,490 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 S 50(1) D $381.36 586,440 I Ernest Irrevocable 2004 Trust III(3)
Class A Common Stock 08/01/2025 S 50(1) D $381.36 686,440 I Ernest C. Garcia III Multi-Generational Trust III(4)
Class A Common Stock 08/01/2025 F 1,229(16) D $367.78 923,155 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.
2. This transaction was executed in multiple trades at prices ranging from $365.02 to $365.54 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
3. These shares of Class A Common Stock are held directly by the Ernest Irrevocable 2004 Trust III (the "Irrevocable Trust"). The Reporting Person is the Investment Trustee and Co-Administrative Trustee of the Irrevocable Trust.
4. These shares of Class A Common Stock are held directly by the Ernest C. Garcia III Multi-Generational Trust III (the "Multi-Generational Trust"). The Reporting Person is the Investment Trustee and Co-Administrative Trustee of the Multi-Generational Trust.
5. This transaction was executed in multiple trades at prices ranging from $366.32 to $367.27 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
6. This transaction was executed in multiple trades at prices ranging from $367.42 to $368.40, inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
7. This transaction was executed in multiple trades at prices ranging from $368.43 to $368.90 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
8. This transaction was executed in multiple trades at prices ranging from $369.49 to $370.49 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
9. This transaction was executed in multiple trades at prices ranging from $370.53 to $371.41, inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
10. This transaction was executed in multiple trades at prices ranging from $371.63 to $372.63 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
11. This transaction was executed in multiple trades at prices ranging from $372.67 to $373.59 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
12. This transaction was executed in multiple trades at prices ranging from $374.06 to $374.85 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
13. This transaction was executed in multiple trades at prices ranging from $375.29 to $376.17 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
14. This transaction was executed in multiple trades at prices ranging from $376.57 to $377.47 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
15. This transaction was executed in multiple trades at prices ranging from $377.58 to $378.30 inclusive. The price reported above reflects the volume weighted average sale price. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
16. Represents total number of shares of Class A Common Stock of the Issuer withheld for taxes upon vesting of restricted stock units pursuant to various awards.
Remarks:
/s/ Paul Breaux, by Power of Attorney for Ernest C. Garcia, III 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many agilon health (AGL) shares did Denise Zamore dispose of?

The filing shows 915 common shares were withheld by the issuer to cover taxes.

Was the transaction an open-market sale of AGL stock?

No. Code "F" denotes share withholding for tax purposes, not an open-market sale.

What is Zamore's total direct ownership after the transaction?

After the withholding, Zamore directly owns 443,125 AGL shares, including RSUs.

Were any derivative securities (options, warrants) involved?

No derivative securities were acquired or disposed of in this Form 4.

Does this Form 4 indicate a change in insider sentiment toward AGL?

The transaction is routine and tax-driven, so it does not provide a meaningful sentiment signal.
Carvana

NYSE:CVNA

CVNA Rankings

CVNA Latest News

CVNA Latest SEC Filings

CVNA Stock Data

50.78B
134.31M
2.61%
89.85%
9.26%
Auto & Truck Dealerships
Retail-auto Dealers & Gasoline Stations
United States
TEMPE